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INTRODUCTION 
The coronavirus disease 2019 (COVID-19) pandemic 
caused by severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) is continuing to cause substantial widespread 
morbidity and mortality worldwide (1). Cellular immunity 
may be critical in an individual’s response to SARS-CoV-2 in-
fection, particularly in the face of neutralizing-antibody 
(nAb) escape by emerging variants, and for reducing the se-
verity of COVID-19 disease. Cases of asymptomatic COVID-19 
have been associated with T cell responses without serocon-
version, suggesting a role for T cell responses following SARS-
CoV-2 exposure in the absence of nAbs (2). Furthermore, 
studies of patients with COVID-19 show that the presence of 
SARS-CoV-2–specific CD4+ and CD8+ T cells are associated 
with lower disease severity (3–5). SARS-CoV-2 vaccines have 
also been shown to elicit T cell responses (6–10), but more in-
depth analyses of the functionality and breadth of vaccine-
specific T cells could provide valuable information on poten-
tial determinants of protection. 
AZD1222 (ChAdOx1 nCoV-19) is a replication-deficient 
simian adenovirus-vectored vaccine indicated for the preven-
tion of COVID-19. The safety, efficacy, and immunogenicity 
of AZD1222 has been extensively demonstrated in a global 
clinical development program, supporting regulatory submis-
sions for conditional or emergency use of AZD1222 (11–14). In 
a phase 1/2 trial conducted in the United Kingdom, COV001, 
AZD1222 induced marked increases in SARS-CoV-2 spike pro-
tein-specific effector T cell responses in adults aged 18–55 
years, which peaked at Day 14 post vaccination. These re-
sponses were reported as early as Day 8 and were maintained 
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through Day 56, which was the latest timepoint analyzed (12). 
Similar responses were reported in adults aged 18 to ≥70 
years in a phase 2/3 study conducted in the United Kingdom, 
COV002, in which SARS-CoV-2 spike protein-specific effector 
T cell responses peaked at Day 14 post vaccination (13). Peak 
responses in adults 18 to 55 years old were characterized by 
interferon (IFN)-γ-, interleukin (IL)-2-, and tumor necrosis 
factor (TNF)-producing T cell helper type 1 (Th1) CD4+ T cells 
and CD8+ T cells (11). However, the cytokine profile of 
AZD1222-induced T cell responses beyond Day 14 in younger 
adults or following a second dose of AZD1222 remains un-
known. Furthermore, a full characterization of AZD1222-
induced T cell cytokine responses in adults older than 55 is 
also undetermined (11). 
Here, we aimed to characterize functional CD4+ and CD8+ 
T cell responses following the first and second doses of 
AZD1222 in healthy adults aged 18 to 85 years enrolled in 
phase 1–3 trials conducted in the United Kingdom. Further-
more, we describe the breadth and depth of unique SARS-
CoV-2 spike protein-specific T cell responses induced by 
AZD1222 vaccination. These data provide a comprehensive 




Evaluable samples were obtained from 296 participants 
enrolled in the COV001 and COV002 studies. Participant 
samples analyzed in this study were selected from three dif-
ferent age cohorts who received two doses of either 5×1010 vi-
rus particles of AZD1222 or control meningococcal conjugate 
vaccine (MenACWY) (Table 1). Of the 296 participants, 83 
participants were analyzed for spike protein-specific cytokine 
secretion by intracellular cytokine staining (ICS) and 233 
were analyzed by T cell receptor (TCR) sequencing. Twenty 
participants had samples in both sets of analyses. 
AZD1222 induced strong Th1-biased T cell responses 
to the SARS-CoV-2 spike protein 
SARS-CoV-2 spike protein-specific T cell responses from 
all participants vaccinated with AZD1222 or MenACWY were 
assessed by measuring intracellular cytokine production in 
peripheral blood mononuclear cells (PBMCs) following in 
vitro stimulation with two separate overlapping peptide 
pools covering the entire SARS-CoV-2 spike protein sequence. 
Total spike protein-specific Th1 responses significantly in-
creased from a median frequency of 0.01% (interquartile 
range [IQR], 0.00 to 0.03) at Day 0 to 0.063% (IQR, 0.04 to 
0.11) in AZD1222-vaccinated participants at Day 28 post vac-
cination and 0.062% (IQR, 0.04 to 0.10) at Day 56 post vac-
cination (4 weeks following the second dose) (P <0.0001, Fig. 
1A, table S1). In MenACWY-vaccinated participants, no in-
creases in the median frequencies of spike protein-specific 
Th1 responses were observed over time. Th1 responses in 
AZD1222-vaccinated participants were significantly greater 
than the median frequencies from those who received Men-
ACWY at both Day 28 (0.01% median frequency, IQR, 0.00 to 
0.02, P <0.0001) and Day 56 (0.02% median frequency, IQR 
0.01 to 0.02, P <0.0001) post vaccination, although lower than 
responses observed in COVID-19 convalescent patients 
(0.13% median frequency, IQR 0.12 to 0.21) (fig. S1A). The Th1 
response followed a hierarchical pattern of cytokine produc-
tion, with most spike protein-specific Th1 cells producing 
TNF (0.06% median frequency, IQR 0.03 to 0.08), followed by 
IL-2 (0.04% median frequency, IQR 0.02 to 0.07) and IFN-γ 
(0.03 median frequency, IQR 0.01 to 0.04) at Day 56 post vac-
cination (Fig. 1B and fig. S1B). Spike protein-specific Th2 re-
sponses were near absent following AZD1222 vaccination 
(Fig. 1C and D and fig. S1C). 
In comparison with the Th1 response, total spike protein-
specific CD8+ T cells were detected at lower frequencies at 
Day 28 and Day 56 post vaccination. However, at Day 56 post 
AZD1222 vaccination, the 0.34% (IQR, 0.02 to 0.07) median 
frequency of spike protein-specific CD8+ T cells was signifi-
cantly elevated compared with the 0.04% median frequency 
(IQR, 0.00 to 0.02, P <0.0001) at Day 0 and compared with 
the median frequency of 0.01% (IQR, 0.00 to 0.06, P = 0.0296) 
at Day 56 in participants vaccinated with MenACWY (Fig. 1E, 
table S1). Spike protein-specific CD8+ T cell responses in-
duced by AZD1222 were also equivalent to those observed in 
COVID-19 convalescent patients (0.04% median frequency, 
IQR 0.02 to 0.10) (fig. S2A). In contrast to the Th1 response, 
at Day 56 most spike protein-specific CD8+ T cells produced 
IFN-γ with a median frequency of 0.03% (IQR, 0.01 to 0.07), 
followed by TNF (0.02% median frequency, IQR 0.01 to 0.05) 
and IL-2 (0.01% median frequency, IQR 0.00 to 0.03) (Fig. 1F 
and fig. S2B). Utilizing a two-fold increase in any spike pro-
tein-specific CD4+ and CD8+ T cell responses, study partici-
pants vaccinated with AZD1222 induced response rates of 
79.2% and 68.6%, respectively, 28 days after a second dose 
(table S2). These data demonstrate that AZD1222 elicited a 
robust Th1-dominated T cell response with an expanded CD8+ 
T cell response post vaccination compared with Day 0, albeit 
at a smaller magnitude than the CD4+ response. 
AZD1222 vaccination generated a polyfunctional 
CD4+ T cell cytokine response across adult age groups 
To determine if CD4+ T cell responses to AZD1222 vaccina-
tion varied by age, subgroup analyses according to partici-
pants’ age (18 to 55, 56 to 69, and ≥70 years) were performed. 
Significant increases in spike protein-specific CD4+ T cell re-
sponses at Day 28 over Day 0 were observed for participants 
within each age group (18 to 55, P <0.0001; 56 to 69, P = 
0.0015; ≥70 years, P = 0.0024, Fig. 2A). The median frequency 
of spike protein-specific CD4+ T cells producing any Th1 cy-
tokine increased from 0.00% (IQR 0.00 to 0.02) at Day 0 to 
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0.02% (IQR, 0.01 to 0.05) at Day 0 to 0.08% (IQR, 0.04 to 0.11) 
at Day 56 for 56 to 69-year-olds, and 0.01% (IQR, 0.00 to 0.02) 
at Day 0 to 0.06% (IQR, 0.04 to 0.08) at Day 56 in ≥70-year-
olds. Individual Th1 cytokine production followed a similar 
hierarchical pattern within each age group (TNF>IL-2>IFN-
γ) (Fig. 2A, fig. S3A and table S3). However, the kinetics of 
the AZD1222-specific Th1 cell response differed by age. In 
participants aged 18 to 55 years, the median frequency of 
spike protein-specific CD4+ T cells producing any Th1 cyto-
kine increased to 0.06% (IQR, 0.04 to 0.09) at Day 28 and 
remained at a consistent frequency through Day 56 post vac-
cination (Fig. 2A). In participants aged 55 to 69 years, the 
spike protein-specific Th1 any response median frequency 
peaked at 0.13% (IQR, 0.07 to 0.16) on Day 28 and declined 
by Day 56, despite receiving a second vaccine dose. Although 
Th1 cell responses observed at Day 28 post vaccination were 
at a lower frequency in participants aged ≥70 years compared 
with other age groups (0.04% median frequency, IQR 0.02 to 
0.06), spike protein-specific responses demonstrated an in-
creased frequency at Day 56, potentially aided by the second 
vaccine dose at Day 28. Importantly, no age-specific differ-
ences in AZD1222-specific Th1 cell responses were observed 
at Day 56. 
The frequencies (Fig. 2B) and proportions (Fig. 2C) of 
AZD1222-specific Th1 cells producing each combination of 
Th1 cytokines were compared among age groups at Day 28 
and Day 56 post vaccination. Spike protein-specific Th1 cells 
displayed a high degree of polyfunctionality at Day 28 post 
vaccination in all three age groups with 50% of the spike pro-
tein-specific CD4+ T cells in 18 to 55-year-olds and 65% of the 
responses in 56 to 69- and ≥70-year-olds producing two or 
more Th1 cytokines. Spike protein-specific Th1 cells remained 
polyfunctional through Day 56 among participants aged 56 
to 69 and ≥70 years. However, in participants aged 18 to 55 
years, the proportion of polyfunctional spike protein-specific 
Th1 cells increased to 64%. Furthermore at Day 56, spike pro-
tein-specific Th1 cells producing all three cytokines repre-
sented 32% of the response in participants aged 18 to 55, 28% 
in participants aged 56 to 69 years and 23% in participants 
aged ≥70 years. These data show that AZD1222 induces a 
polyfunctional Th1 cell response that is equivalent in fre-
quency and functionality across all adult age groups at Day 
56 post vaccination. 
Polyfunctional CD8+ T cell responses are generated 
following AZD1222 vaccination 
AZD1222-specific CD8+ T cell responses were generated in 
all age groups, but at lower frequencies compared with the 
Th1 responses. Spike protein-specific CD8+ T cell responses 
peaked at Day 28 post vaccination in participants aged 18 to 
55 years (0.04% median frequency, IQR 0.00 to 0.07) and 56 
to 69 years (0.02% median frequency, IQR 0.01 to 0.05), with 
little change at Day 56 for 18 to 55-year-olds (0.03% median 
frequency, IQR 0.01 to 0.11) or 56 to 69-year-olds (0.03% me-
dian frequency, IQR 0.02 to 0.07) (Fig. 3A, fig. S3B, and table 
S3). However, participants aged ≥70 years seemed to benefit 
from a second vaccine dose, as significant expansion of spike 
protein-specific CD8+ T cells was observed at Day 56 post vac-
cination (0.03% median frequency, IQR 0.02 to 0.06) above 
Day 0 (0.01% median frequency, IQR 0.00 to 0.03, P = 0.0103) 
and Day 28 (0.01% median frequency, IQR 0.00 to 0.02, P = 
0.0050). Importantly, by Day 56, no statistical differences in 
spike protein-specific CD8+ T cell responses were observed 
among age groups. 
The frequency and proportion of each combination of 
spike protein-specific CD8+ T cell cytokines was also exam-
ined for each age group. At Day 28 post vaccination, 51% of 
spike protein-specific CD8+ T cells in participants aged 18 to 
55 and 58% of spike protein-specific CD8 T cells in partici-
pants ≥70 years only produced a single cytokine (Fig. 3B and 
C). However, participants aged 56 to 69 years generated a 
multicytokine response at Day 28 post vaccination with 72% 
of spike protein-specific CD8+ T cells producing two or more 
cytokines. Although the total frequency of spike protein-spe-
cific CD8+ T cells in participants aged 18 to 55 years did not 
increase from Day 28 through Day 56, the proportion of mul-
ticytokine-producing cells increased to 74% of all responding 
CD8+ T cells, with 32% of responding CD8+ T cells producing 
TNF, IL-2, and IFN-γ. Frequencies of polyfunctional, spike 
protein-specific CD8+ T cells in participants aged ≥70 years 
also increased from Day 28 through Day 56, with 23% pro-
ducing TNF, IL-2, and IFN-γ at Day 56. Together, these data 
demonstrate that AZD1222-specific CD8+ T cells are largely 
polyfunctional, and that the size of the response is equivalent 
across all age groups at Day 56 post vaccination. The correla-
tion between magnitude of nAb response and frequency of 
spike protein-specific CD4+ Th1 T cell response was further 
examined in a subset of AZD1222 and MenACWY vaccinated 
study participants (fig. S4). Although no correlations were ob-
served between magnitude of nAb responses and frequency 
of Th1 responses after a first or second dose of AZD1222, this 
may be influenced by the limited sample size (n=34) for 
which both humoral and cell mediated responses were avail-
able. If these data are observed in a larger cohort, it may in-
dicate that T cell responses can complement a lower-
magnitude nAb response in those vaccinated with AZD1222. 
AZD1222-specific T cell responses were genetically 
diverse and covered a broad range of SARS-CoV-2 spike 
protein epitopes 
To better understand the diversity and specificity of the T 
cell response to SARS-CoV-2 spike protein following AZD1222 
vaccination, TCRβ chain sequencing was performed on 233 
PBMC samples collected at Day 0 and Day 28 post second 
dose. Individual TCRs in each repertoire were compared 
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CoV-2 that had been generated using the Multiplex Identifi-
cation of T cell Receptor Antigen Specificity (MIRA) platform 
(15). The total number of unique and total antigen-specific 
TCRs pre and post vaccination were characterized for each 
repertoire. PBMCs from study participants treated with two 
doses of AZD1222 at different dose intervals were used to in-
crease the power of the TCR repertoire analysis. In addition 
to the participants used in the ICS analysis who received a 
second dose at approximately 4 weeks (18 to 60 days) post 
initial vaccination, a second cohort of participants who re-
ceived a second dose at approximately 12 weeks (61 to 130 
days) post vaccination were also analyzed. Participants vac-
cinated with AZD1222 at approximately 4-week and approxi-
mately 12-week second dose schedules both had a significant 
increase in the fraction of total T cells that were spike pro-
tein-specific (SARS-CoV-2–associated T cells of total T cells; 
depth) (P <0.0001, fig. S5A) and fraction of unique TCRs that 
were spike protein-specific (SARS-CoV-2–associated unique 
TCRs of total unique TCRs; breadth) (fig. S5B) post second 
dose. There was no statistical difference in either the depth 
or the breadth of the responses between the two dosing regi-
mens. Because of this equivalency, data from these two dos-
ing regimens were combined into single “Day 0” and “Day 28 
post second dose” groups. 
Looking first at the breadth of spike protein-specific TCRs 
from AZD1222-vaccinated participants, a significant increase 
was observed from Day 0 to Day 28 post second dose (P 
<0.0001, Fig. 4A). Furthermore, spike protein-specific TCR 
breadth was also significantly elevated in AZD1222-
vaccinated participants compared with MenACWY-vac-
cinated participants at Day 28 post second dose (P <0.0001, 
Fig. 4A). No increase in TCR breadth of non-spike protein-
specific SARS-CoV-2 TCRs was observed in either AZD1222- 
or MenACWY-vaccinated participants (fig. S6A). When par-
ticipants were separated by age cohorts, all three age groups 
had a significant increase in spike protein-specific TCR 
breadth from Day 0 to Day 28 post second dose (P <0.0001, 
Fig. 4B). In addition to TCR breadth, total TCR templates 
were also quantified for each group. Further confirming the 
ICS data (Fig. 1), the number of spike protein-specific TCRs, 
or depth, was significantly increased in AZD1222-vaccinated 
participants at Day 28 post second dose compared with Day 
0, and also compared with MenACWY-vaccinated partici-
pants (P <0.0001, Fig. 4C). The trends observed with regards 
to spike protein-specific TCR depth after vaccination were 
the same across age groups, but in the 56 to 69 years group, 
these responses did not meet significance for depth of re-
sponse, likely due to the lower power given the smaller num-
ber of analysis points for this age group (P = 0.14). 
Participants aged 18 to 55 years and ≥70 years displayed sig-
nificant increases in spike protein-specific TCR depth post 
vaccination (P <0.0001, P = 0.0003 respectively, Fig. 4D). 
Additionally, two COVID-19 convalescent patients were se-
quenced and the depth and breadth of spike protein-specific 
T cells were comparable to patients at Day 28 post second 
dose (table S4). There were no changes in depth within non–
spike protein-specific TCRs in AZD1222- or MenACWY-vac-
cinated participants (fig. S6B). 
To better understand the breadth and depth of the T cell 
response in AZD1222-vaccinated participants, each unique 
spike protein-specific TCR sequence was mapped to the re-
gion of the spike protein to which it reacted in the MIRA data 
(15). Spike protein-specific CD4+ T cell responses spanned the 
entire spike protein (Fig. 5A and B and table S5). Dominant 
responses (those with the highest frequency) were observed 
in the N-terminal region 160–218 and the C-terminal side 
743–854. Fewer unique spike protein-specific CD8+ T cell 
TCRs were sequenced, likely due to the lower response post 
vaccination at these timepoints (Fig. 1) and the greater hu-
man leukocyte antigen (HLA) restriction of class I peptides. 
Half of all unique CD8+ TCRs mapped to a single region of 
the spike protein, with the other TCRs spread evenly across 
the other regions (Fig. 5C and D). Overlaying known muta-
tions in variants of concern, including B.1.1.7 and B.1.351, in-
dicates that although nearly 30% of unique TCRs mapped to 
a single region of the spike protein that is mutated in the 
B.1.351 SARS-CoV-2 variant, nearly half of all unique spike 
protein-specific TCRs recognized epitopes outside of the mu-
tated regions found in the B.1.351 and B.1.1.7 variants. More-
over, the mutation within this single region is a single point 
mutation, D215G. Therefore, these data demonstrate that 
AZD1222 vaccination induces an expansion of SARS-CoV-2 
spike protein-specific T cells with TCR sequences that map to 
a number of epitopes across the entire spike protein. 
DISCUSSION 
Correlates of protection against COVID-19 are currently 
undetermined (16); however, cellular immunity is associated 
with positive outcomes (3–5). Here, we have provided a com-
prehensive assessment of the T cell response to AZD1222 vac-
cination. AZD1222 vaccination elicited a robust and 
polyfunctional Th1-dominated T cell response to the SARS-
CoV-2 spike protein with a spike protein-specific CD8+ T cell 
response across all age groups 28 days post second dose. 
These responses may be critical in reducing the clinical symp-
toms associated with COVID-19 disease, as evidenced by lon-
gitudinal follow-up of patients with SARS-CoV-2 infection, 
where rapid CD4+ T cell responses in acute COVID-19 were 
shown to be associated with mild disease and accelerated vi-
ral clearance, and early appearance of SARS-CoV-2–specific T 
cells was associated with shorter duration of infection (17). In 
a study that measured SARS-CoV-2–specific antibodies, CD4+, 
and CD8+ T cells in participants with a range of COVID-19 
disease severities, severe or fatal disease was shown to be as-
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and CD8+ T cell responses (3). Furthermore, SARS-CoV-2–
specific CD4+ T cells were associated with less severe disease. 
SARS-CoV-2–specific CD8+ T cells were also associated with 
lower disease severity, reinforcing the potential importance 
of T cell-mediated immunity for minimizing disease caused 
by SARS-CoV-2 infection. Finally, there is evidence with some 
vaccinations, such as influenza, that T cell-mediated immun-
ity may be a more reliable correlate of protection than anti-
body responses in older adults (18). The AZD1222 primed T 
cell responses that formed across all age groups may provide 
critical protection from severe illness due to COVID-19, as 
seen in vaccinated participants in these trials. 
Strong Th1 responses are an important safety indicator for 
vaccines against respiratory pathogens. Previous whole inac-
tivated virus vaccines for measles (19) and respiratory syncyt-
ial virus (20) led to vaccine-associated enhanced respiratory 
disease (VAERD). This disease, characterized by an intense 
allergic inflammation of the airways, is driven by vaccine-spe-
cific Th2 cells (21). Furthermore, vaccination of mice with 
SARS-CoV-1 and Middle East respiratory syndrome corona-
virus (MERS-CoV) vaccines has been shown to result in im-
munopathology that was attributed to Th2-biased responses 
(22, 23). Th1-predominant responses and balanced CD4+ and 
CD8+ T cell responses are less likely to induce immunopathol-
ogy and are therefore preferred COVID-19 vaccine character-
istics. Importantly, spike protein-specific Th2 responses were 
minimal following AZD1222 vaccination in all age groups. 
These data are consistent with other SARS-CoV-2 vaccines, in 
which similar Th1-dominated responses have been reported 
(6–9). 
When we further characterized this T cell response, the 
majority of spike protein-specific Th1 and CD8+ T cells were 
polyfunctional across all age groups. Whereas previous data 
have suggested that T cells, as analyzed by IFN-γ ELISpot, do 
not increase following a second dose of AZD1222, the in-
creases in polyfunctionality that are seen post second dose 
suggest that the quality, rather than quantity, of the response 
may be improved by a two-dose regimen. The quality of the T 
cell response by cytokine characterization can give clues as to 
how well T cells are performing effector functions and organ-
izing immune responses (24). Numerous studies have demon-
strated that both vaccine and infection-elicited, 
multicytokine-producing T cells correlate with enhanced pro-
tection against cytomegalovirus (CMV), hepatitis C virus, hu-
man herpesvirus-8, human immunodeficiency virus, 
influenza virus, yellow fever virus, and Leishmania major 
(25–30). The polyfunctional responses that we observe in our 
analyses therefore support the contribution of T cell immun-
ity to the protective effect of AZD1222 vaccination. Although 
there was more limited polyfunctionality of CD8+ T cell re-
sponses after the first dose of AZD1222 in adults aged ≥70 
years, after a second dose, CD8+ T cells improved in quantity 
and polyfunctionality. Therefore, two doses of AZD1222 may 
be required in adults aged ≥70 years to achieve the same de-
gree of polyfunctionality that is achieved in other age groups 
following the first dose. Data from clinical trials and emerg-
ing real-world evidence in individuals aged ≥65 has demon-
strated the effectiveness of AZD1222 for protection of COVID-
19 disease following one or two doses (13, 31–33). 
Although T cells are important for minimizing disease 
caused by SARS-CoV-2, nAbs have also been found to be as-
sociated with protection against reinfection (34). B cells de-
pend upon CD4+ T cell help for the development of pathogen-
specific antibody responses (35). In fact, anti-spike protein 
receptor-binding domain (RBD) antibody responses in pa-
tients who have recovered from COVID-19 correlated with the 
magnitude of spike protein-specific CD4+ T cell responses 
(36). Such antibody responses are facilitated specifically by a 
subset of CD4+ T cells called T follicular helper (Tfh) cells 
through the development of germinal centers in secondary 
lymphoid tissues (37). Circulating Tfh cells have been de-
tected in patients who have recovered from COVID-19 (38) 
and have even been shown to be prominent among specific 
CD4+ T cells in individuals during acute COVID-19 or after 
convalescence (3). Characterizing the frequency and pheno-
type of circulating Tfh cells following AZD1222 vaccination 
may be informative to future studies. 
In the present study, AZD1222-expanded T cells were re-
active to a variety of epitopes spanning the length of spike 
protein. Analysis by TCR sequencing (TCRseq) showed an in-
crease in both breadth and depth across multiple epitopes of 
the SARS-CoV-2 spike protein. Increased T cell breadth is an 
important protective mechanism against viruses that genet-
ically diverge from parental strains (39–42). Recently, the 
SARS-CoV-2 spike genome has accumulated mutations, re-
sulting in the emergence of SARS-CoV-2 variants, including 
the B.1.351 lineage that was first identified in South Africa, 
and the B.1.1.7 lineage that was first identified in the United 
Kingdom (43, 44). Efficacy of AZD1222 against SARS-CoV-2 
variants B.1.351 and B.1.1.7 investigated in Syrian hamsters 
showed that, despite an observed reduction in nAb titers 
against B.1.351 in AZD1222-vaccinated hamsters compared 
with those against B.1.1.7, there was evidence of protection in 
the lower respiratory tract against both variants post 
AZD1222 vaccination (45). AZD1222 vaccination has been 
shown to provide protection against symptomatic disease in 
adults aged ≥18 years caused by the B.1.1.7 lineage, shortening 
the duration of shedding and viral load, which may result in 
reduced transmission of disease (46). Although AZD1222 was 
not able to prevent mild to moderate symptomatic infection 
against B.1.351 in humans, we believe the vaccine may still 
play a protective role against severe disease and further study 
is warranted. Importantly, recent studies in patients exposed 
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responses were not affected by mutations found in the B.1.351 
and B.1.1.7 variants (47, 48). The breadth of T cell responses 
across multiple viral epitopes spanning the length of SARS-
CoV-2 spike protein following vaccination with AZD1222 is 
similar to the response following Ad26.CoV2.S vaccination 
(49) and suggests that the cellular immune response to 
AZD1222 may be resilient to point mutations in SARS-CoV-2. 
Limitations of the study included that it was run in the 
United Kingdom, with a majority of participants who were 
white and of British descent, and with more females than 
males in the overall population. This may have therefore re-
sulted in underestimating clonal diversity induced by 
AZD1222, due to a population with a more limited HLA pro-
file and may be a factor responsible for reduced spike protein-
specific CD8+ T cell clonal diversity and lower frequencies 
compared with corresponding Th1 responses. Furthermore, 
spike protein-specific CD8+ T cell frequencies may have been 
reduced because samples were analyzed at Day 28 post vac-
cination, which is 2 weeks past the peak timepoint of the T 
cell responses (13), although they were still comparable to 
CD8+ T cell responses. Lack of availability of biospecimens at 
the Day 14 timepoint in the present study prevented analyses 
of AZD1222-induced T cell responses against SARS-CoV-2 and 
characterization of the TCR repertoire at this peak timepoint. 
Furthermore, in this study, only six participants vaccinated 
with AZD1222 were seropositive at Day 0, providing limited 
data for the effect of AZD1222 vaccination on seropositive 
participants. Despite these study limitations, our observa-
tions are still consistent with data that SARS-CoV-2–specific 
CD4+ T cell responses are more prominent than CD8+ T cell 
responses following infection (36) and vaccination (7, 8, 10). 
In summary, a combination of antibody and T cell im-
munity is likely needed to provide long-term protection 
against SARS-CoV-2 infection (50). Previous studies have 
shown that AZD1222 leads to a robust nAb response across 
multiple age groups (12, 13). Here, we demonstrate that 
AZD1222 vaccination also induces a polyfunctional Th1-dom-
inated T cell response to SARS-CoV-2 spike protein in all 
adult age groups, including expansion of SARS-CoV-2 spike 
protein-specific CD4+ and CD8+ T cells, with unique TCR se-
quences that mapped to multiple epitope regions across the 
entire spike protein, which may provide long-lasting protec-
tion from severe disease associated with SARS-CoV-2 vari-
ants. 
MATERIALS AND METHODS 
Study design 
Healthy adults aged 18 to ≥70 years were enrolled in a sin-
gle-blind, randomized, controlled, phase 2/3 trial for the 
SARS-CoV-2 vaccine, AZD1222 (ChAdOx1 nCoV-19), as de-
scribed in the previously published safety and immunogenic-
ity report (13). Full descriptions of the methods of the studies 
have been previously published, including full study 
protocols (12, 13). Briefly, participants were enrolled in an 
age-escalation manner, into 18 to 55 years, 56 to 69 years, and 
≥70 years immunogenicity subgroups. Participants were ran-
domly assigned to receive either AZD1222 or control Men-
ACWY, using block randomisation. Due to a dosing error in 
the study, some participants received a low dose (2·2×1010 vi-
rus particles) rather than the intended standard dose (5×1010 
virus particles) as their first dose. A licensed vaccine compar-
ator such as MenACWY has the potential to provide a benefit 
to participants (prevention of infection with Neisseria men-
ingitidis) and facilitates the participant blinding, who, upon 
control vaccination, may experience local and general ad-
verse events similar to those experienced by those vaccinated 
with the experimental vaccine. Participants aged 18 to 55 
years were randomly assigned (1:1) to either two doses of 
AZD1222 or two doses of MenACWY. Participants aged 56 to 
69 years were randomly assigned (3:1:3:1) to one dose of 
AZD1222, one dose of MenACWY, two doses of AZD1222, or 
two doses of MenACWY. Participants aged ≥70 years were 
randomly assigned (5:1:5:1) to one dose of AZD1222, one dose 
of MenACWY, two doses of AZD1222, or two doses of Men-
ACWY. Prime-booster regimens were given 28 days apart. 
Participants were then recruited to the standard-dose cohort 
(5×1010 virus particles of AZD1222) and the same randomisa-
tion procedures were followed, except pariticipants aged 18 
to 55 years were randomly assigned in a 5:1 ratio to two doses 
of AZD1222 or two doses of MenACWY. Participants, clinical 
investigators, and the laboratory team, but not staff adminis-
tering the vaccine, were masked to vaccine allocation for the 
duration of the study. 
For the analysis performed in this study, participant sam-
ples, for whom PBMCs were available at matched timepoints, 
were selected from all three age cohorts who received either 
two doses of AZD1222 (5×1010 virus particles) or control Men-
ACWY (Table 1). In total, samples were obtained from 296 
unique participants in studies COV001 and COV002. A win-
dowing convention was applied to ICS and TCRseq data. For 
ICS, Day 28 refers to 28 ±7 days after the first dose and Day 
56 refers to 28 ±7 days from the second dose (or approxi-
mately 56 days post the first dose). Written informed consent 
was obtained from all participants, and the trials were done 
in accordance with the principles of the Declaration of Hel-
sinki and Good Clinical Practice. COV001 was approved in the 
United Kingdom by the Medicines and Healthcare products 
Regulatory Agency (reference 21584/0424/001-0001) and the 
South-Central Berkshire Research Ethics Committee (refer-
ence 20/SC/0145). COV002 was sponsored by the University 
of Oxford and approved in the United Kingdom by the Medi-
cines and Healthcare products Regulatory Agency (reference 
21584/0428/001-0001) and the South-Central Berkshire Re-
search Ethics Committee (reference 20/SC/0179). Vaccine use 
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Committees at each participating site. 
Samples from 83 participants were used for ICS analysis 
and samples from 233 participants for TCR analysis, with 20 
participant samples present in both datasets (Table 1). One 
patient in TCR analysis from the 18 to 55 age group was con-
firmed to have received a lower first dose (2.25×1010 virus par-
ticles) and a standard second dose (5×1010 virus particles) of 
AZD1222. 
ICS assay and analysis 
PBMCs were isolated from vaccine recipient blood sam-
ples within 6 hours of venipuncture and cryopreserved at be-
low –150°C prior to use in ICS assays. Human convalescent 
samples were obtained following symptom onset from adults 
with previous SARS-CoV-2 infection. Specimens were col-
lected after participants provided written informed consent 
under an institutional review board approved protocol at the 
National Institutes of Health Clinical Center (NCT00067054). 
PBMCs were isolated and cryopreserved similarly to those 
from vaccine recipients. ICS was performed on samples ob-
tained at Day 0, Day 28, second dose (if different than Day 
28), and Day 28 post second dose. 
Antibody titration of all antibodies included in the analy-
sis was performed prior to the analysis of clinical specimens. 
The ICS assay was used to evaluate T cell responses, as previ-
ously described (10). Briefly, PBMCs were thawed and rested 
overnight before being stimulated with pools of 15-mer pep-
tides overlapping by 10 amino acids covering the N terminus 
of SARS-CoV-2 spike protein up to the furin cleavage site (S1 
pool) and the C terminus of the SARS-CoV-2 spike protein up 
to the furin cleavage site (S2 pool) for 6 hours at 37°C with 
5% CO2. Peptide pools were custom ordered from JPT Peptide 
Technologies GmbH and were >85% pure. 
Following stimulation, cells were stained and analyzed as 
described previously (51). Briefly, cells were washed with 
phosphate-buffered saline (PBS) and stained with viability 
dye for 20 min at room temperature, followed by surface stain 
for 20 min at room temperature, cell fixation, and permea-
bilization with BD cytofix/cytoperm kit (catalog # 554714) for 
20 min at room temperature, and then intracellular stain for 
20 min at room temperature. All antibody staining was per-
formed in the dark. Surface staining and all pre-fixation 
washes were performed with FACS buffer (PBS + 1% FBS + 
0.02% NaN3) and intracellular staining and post-fixation 
washes were performed in 1X BD Perm/Wash buffer (BD Bi-
osciences, catalog # 554714). See table S6 for a complete list 
of antibodies used. Upon completion of staining, cells were 
collected on a BD FACSymphony Flow Cytometer. Samples 
were invalidated if <20,000 live CD3+ T cells were collected. 
On average, ≥280,000 were collected for each sample. Sam-
ples were analyzed using FlowJo 10.6.2 (BD Biosciences). 
Anomalous “bad” events were separated from “good” events 
using FlowAI (52). “Good events” were used for all 
downstream gating. Gating strategy can be found in fig. S7. 
Individual cytokines were plotted on the Y-axis versus CD69+ 
cells on the X-axis, and only CD69+ events were used to de-
termine positive responses. No cytokine-positive responses 
were detected above background in the CD69- gate. Repre-
sentative flow plots for cytokine gating are shown in fig. S8. 
CD69+ activated cells were increased over baseline following 
AZD1222 vaccination but did not differ between peptide 
pools or by age groups (fig. S9). All antigen-specific cytokine 
frequencies are reported after background subtraction of 
identical gates from the same sample incubated with negative 
control stimulation with dimethyl sulfoxide (DMSO). 
Assay qualification was performed by the Vaccine Immu-
nology Program at the Vaccine Research Center, National In-
stitute of Allergy and Infectious Diseases, National Institutes 
of Health. Assay qualification included assessment of Th1 and 
Th2 specificity, Th1 and Th2 intra-assay precision, inter-assay 
precision, and SARS-CoV-2 peptide pool validation. Th1 and 
Th2 specificity was conducted by utilizing PBMCs from 
acutely infected CMV donors (for Th1 specificity) or Filaria 
parasite donors (for Th2 specificity), given the established cy-
tokine profiles of these pathogens. 
T cell receptor β chain sequencing 
Immunosequencing of the CDR3 regions of human TCRβ 
chains was performed using the ImmunoSEQ Assay (Adap-
tive Biotechnologies). Extracted genomic DNA was amplified 
in a bias-controlled multiplex polymerase chain reaction 
(PCR), followed by high-throughput sequencing. Sequences 
were collapsed and filtered to identify and quantitate the ab-
solute abundance of each unique TCRβ complementarity-de-
termining region (CDR)3 region for further analysis as 
previously described (53–55). The fraction of T cells was cal-
culated by normalizing TCRβ template counts to the total 
amount of DNA usable for TCRseq, where the amount of us-
able DNA was determined by PCR amplification and sequenc-
ing of several reference genes that are expected to be present 
in all nucleated cells. 
Mapping of SARS-CoV-2 TCRβ sequences 
TCR sequences from participants receiving AZD1222 were 
mapped against a set of TCR sequences that are known to 
react to SARS-CoV-2. Briefly, these sequences were first iden-
tified by MIRA (56). TCRs that reacted were further screened 
for enrichment in COVID-19–positive repertoires collected as 
part of immuneCODE (15) and compared with COVID-19–
negative repertoires to remove TCRs that may be highly pub-
lic or cross-reactive to common antigens. Individual response 
could be quantified by the number or frequency of SARS-CoV-
2 TCRs seen post-vaccination. TCRs were further analyzed to 
determine position within spike protein based on the MIRA 
antigens. 
Sequences of known variants were obtained from GISAID 
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locations. Antigens that contain any mutations observed in 
the B.1.1.7 or B.1.351 variants were labeled as potentially im-
pacted. 
Statistical Analysis 
For ICS analysis, significant differences between vaccina-
tion groups were determined by Mann-Whitney nonparamet-
ric two-tailed t tests with a 95% confidence interval. 
Significant differences between timepoints within each vac-
cine group were determined by Kruskal-Wallis nonparamet-
ric one-way analysis of variance (ANOVA) with Dunn’s test to 
correct for multiple comparisons. For all TCR analyses, sig-
nificant differences were determined by one-way ANOVA fol-
lowed by Sidak’s multiple comparisons tests. Raw data are 
available in Data Files S1 and S2. 
SUPPLEMENTARY MATERIALS 
www.science.org/doi/10.1126/scitranslmed.abj7211 
Figs. S1 to S9 
Tables S1 to S6 
Data files S1 and S2 
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Fig. 1. Th1 and CD8+ T cell responses are elicited following vaccination with AZD1222 or MenACWY. PBMCs 
from human participants vaccinated with AZD1222 or MenACWY at the indicated timepoint post vaccination were 
stimulated with SARS-CoV-2 spike peptide pools, and the intracellular cytokine response was measured. (A) 
Frequencies of total spike protein-specific CD4+ T cells producing any combination of Th1 (IFN-γ, IL-2, or TNF) 
cytokines are shown. (B) Frequencies of total spike protein-specific CD4+ T cells producing individual Th1 
cytokines at the indicated timepoints are shown. (C) Frequencies of total spike protein-specific CD4+ T cells 
producing any combination of Th2 (IL-4 or IL-13) cytokines are shown. (D) Frequencies of total spike protein-
specific CD4+ T cells producing individual Th2 cytokines at the indicated timepoints are shown. (E) Frequencies 
of total spike protein-specific CD8+ T cells producing any combination of IFN-γ, IL-2, or TNF following vaccination 
with AZD1222 or MenACWY. (F) Frequencies of individual CD8+ T cell cytokines at the indicated timepoints in 
participants vaccinated with AZD1222. For all data, responses to each peptide pool were combined to determine 
the total spike protein-specific response. In the box and whisker plots, the horizontal line represents median, 
boxes represent interquartile range, whiskers extend to the min and max, and symbols represent each participant. 
Significant differences between AZD1222 and MenACWY at each timepoint were determined by two-tailed Mann-
Whitney tests. Significant differences between timepoints within each vaccine group were determined by Kruskal-
Wallis test with Dunn’s test to correct for multiple comparisons. All comparisons are not significant unless stated 





















































































Fig. 2. Age-specific CD4+ T cell responses are observed following AZD1222 vaccination. (A) Median 
frequencies with interquartile ranges are shown for CD4+ T cells from participants within each age 
cohort producing IFN-γ, IL-2, TNF, or any combination of these cytokines at the indicated timepoints 
following stimulation with SARS-CoV-2 spike peptide pools. Significant differences between timepoints 
within each vaccine group were determined by Kruskal-Wallis tests with Dunn’s test to correct for 
multiple comparisons. All comparisons are not significant unless stated as significant; **p<0.01, 
***p<0.001, ****p<0.0001. (B) Frequencies of antigen-stimulated CD4+ T cells producing each 
combination of IFN-γ, IL-2, TNF cytokines at Day 28 (left) or Day 56 (right) post vaccination are shown. 
Individual participant responses are shown with median represented by the horizontal line. (C) Pie 
graphs indicate the total proportion of spike protein-specific Th1 cytokine production averaged for all 
participants within the indicated age groups at Day 28 and Day 56 post vaccination. Proportion of 






















































































Fig. 3. Age-specific CD8+ T cell responses are elicited after AZD1222 vaccination. (A) 
Median frequencies with interquartile ranges of CD8+ T cells producing IFN-γ, IL-2, TNF, or 
any combination of these cytokines are shown for the indicated timepoints following 
stimulation with SARS-CoV-2 spike peptide pools. Significant differences between 
timepoints within each vaccine group were determined by Kruskal-Wallis tests with Dunn’s 
test to correct for multiple comparisons. All comparisons are not significant unless stated as 
significant; *p<0.05, **p<0.01. (B) Frequencies of antigen-stimulated CD8+ T cells 
producing each combination of IFN-γ, IL-2, TNF cytokines at Day 28 (left) or Day 56 (right) 
post vaccination at the individual level are shown. Individual participant responses are shown 
with median represented by the horizontal line . (C) Pie graphs indicate the total proportion 
of spike protein-specific CD8+ T cell cytokine production within the indicated age groups at 
Day 28 and Day 56 post vaccination. Proportion of multi-cytokine responses are represented 












































Fig. 4. Spike protein-specific TCR breadth and depth increased following vaccination with two 
doses of AZD1222. (A) Spike protein-specific TCR breadth following dose two (D2) of vaccination with 
MenACWY (blue) or AZD1222 (orange) is shown. Breadth indicates SARS-CoV-2–associated unique 
TCRs of total unique TCRs. (B) Spike protein-specific TCR breadth is shown disaggregated by age. (C) 
Spike protein-specific TCR depth following vaccination with MenACWY (blue) or AZD1222 (orange) is 
shown. Depth indicates SARS-CoV-2–associated T cells of total T cells. (D) Spike protein-specific TCR 
depth is shown disaggregated by age. Data are log10 transformed, where all 0 values have been 
converted to half of the lowest nonzero value. In the box and whisker plots, the horizontal line 
represents median, boxes represent interquartile range, whiskers extend to the min and max, and 
symbols represent each participant. The dotted lines represent the lower detected value. Significant 
differences were determined by one-way ANOVA followed by Sidak’s multiple comparisons tests. All 








































  Fig. 5. Spike protein-specific CD4+ and CD8+ T cell responses demonstrate substantial breadth and 
depth across the entire spike protein. TCR sequences from participants vaccinated with AZD1222 at 
Day 28 post second dose were mapped against TCR sequences known to react to SARS-CoV-2. (A and 
B) CD4+ T cell breadth (A) and depth (B) were analyzed for each participant. (C and D) CD8+ T cell 
breadth (C) and depth (D) were analyzed for each participant. The number of participants displaying 
responses for each epitope region is indicated at the top of each plot (n). Sequences of known variants 
were aligned to known Multiplex Identification of T cell Receptor Antigen Specificity (MIRA) antigen 
locations, with any mutations observed in B.1.351 (yellow), B.1.1.7 (blue), or both (red) highlighted. In 
the box and whisker plots, the horizontal line represents median, boxes represent interquartile range, 
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aged 18 to 55 
Patients 





(Day 0 & Day 28 
post dose 2) 
  
MenACWY 




57 20 17 20 55 
Total 83 29 24 30 81 
  MenACWY 26 18 2 6 14 
TCRseq  
AZD1222 207 130 26 51 114 
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